Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study

Alotaibi et al., International Journal of General Medicine, 2021:14
Sep 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -134% Improvement Relative Risk HCQ for COVID-19  Alotaibi et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 437 patients in Saudi Arabia Study compares with favipiravir, results vs. placebo may differ Higher mortality with HCQ (not stat. sig., p=0.051) c19hcq.org Alotaibi et al., Int. J. General Medic.., Sep 2021 FavorsHCQ Favorsfavipiravir 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Retrospective hospitalized patients in Saudi Arabia, showing lower mortality with favipiravir compared to HCQ, not quite reaching statistical significance. Authors do not indicate the factors behind which therapy was chosen. May be subject to significant confounding by indication and confounding by time.
Study covers favipiravir and HCQ.
risk of death, 133.5% higher, RR 2.33, p = 0.05, treatment 193, control 244, multivariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alotaibi et al., 14 Sep 2021, retrospective, Saudi Arabia, peer-reviewed, 11 authors, this trial compares with another treatment - results may be better when compared to placebo.
This PaperHCQAll
Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
Musim Alotaibi, Ahmed Ali, Duaa Bakhshwin, Yasser Alatawi, Sultan Alotaibi, Abdullah Alhifany, Badr Alharthi, Nasser Alharthi, Awatef Alyazidi, Yasmeen Alharthi, Aziza Alrafiah
International Journal of General Medicine, doi:10.2147/ijgm.s329881
Background: Coronavirus disease (COVID-19) is an infectious disease due to SARS-COV -2. Patients with risk factors are vulnerable to severe morbidity and mortality. Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19 treatments. Objective: To investigate the effectiveness and safety of FPV compared to HCQ in patients with COVID-19 as the standard of care approved by the national protocol there. Methods: This is a retrospective cohort study on patients with COVID-19 who were administered either FPV or HCQ at King Faisal Medical Complex, Taif, Saudi Arabia, from June 2020 to August 2020. Results: In total, 508 patients were included in the analysis. Patients were categorized into three groups by medication. Patients enrolled in this study were 244 (55.8%) on FPV, 193 (44.2%) on HCQ and 71 (13.81%) on neither medication. Patients who received FPV had higher age and greater comorbidity. Most of the patients were discharged on day 14 (n = 303, 59.6%), 26 (36.6%) in neither med, 154 (63.1%) in FPV and 123 (63.7%) in HCQ groups with significant difference between groups (P < 0.0001). Mortality rate was 8.2% (n = 20) in FPV and 7.3% (n = 14) in HCQ groups with significant difference between groups (P = 0.048). Regarding drug safety, 19.7% of patients treated with FPV vs 7.8% HCQ have adverse effects with significant difference between groups (P < 0.0001). Most of the side effects were increase ALT and AST. Meanwhile, prolonged Q-T interval was reported only in the HCQ group (2.6%). From Cox regression modeling, only mechanical ventilation due to Covid 19 was predictive for mortality (HR: 16.598, 95% CI: 7.095-38.828, P < 0.0001). Meanwhile, there was no significant difference in the prediction of discharge of FPV (vs HCQ) (HR: 0.933, 95% CI: 0.729-1.195, P = 0.5843), predictors of mortality were HCQ (vs FPV) (HR: 2.3, 95% CI: 0.994-5.487, P = 0.0518). Kaplan-Meier survival curves showed improved survival time and discharged time among patients in the HCQ versus FPV group with an insignificant difference between them (P = 0.85, P = 0.06, respectively). Conclusion: The present study concluded that FPV and HCQ showed comparable efficacy in decrease mortality and oxygen requirements. FPV likely has a more favorable safety profile regarding cardiac toxicity. A randomized clinical trial with large patient numbers is recommended to confirm the effectiveness of these drugs in COVID-19 patients.
Disclosure The authors declare no conflicts of interest in this work. International Journal of General Medicine Dovepress
References
Alotaibi, by TCPDF
Alzeer, Bahammam, Masood, Basha, Alhamad et al., Outcome of patients with severe asthma in the intensive care unit, Ann Saudi Med, doi:10.5144/0256-4947.2006.461
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007
Chen, Huang, Cheng, Favipiravir versus arbidol for COVID-19: a randomized clinical trial, doi:10.1101/2020.03.17.20037432v4#:~:text=Conclusions%20Among%20patients%20with%20COVID,Favipiravir%20are%20mild%20and%20manageable
Chen, Liu, Liu, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J Zhejiang Univ
Chen, Wang, Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia, Clinical Toxicol
Commission, Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial version 8)
Dabbous, El-Sayed, Assal, Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: a randomised controlled trial, Sci Rep, doi:10.1038/s41598-021-85227-0
Furtado, Berwanger, Fonseca, Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial, Lancet, doi:10.1016/S0140-6736(20)31862-6
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Guner, Hasanoglu, Kayaaslan, Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir, J Infect Public Health, doi:10.1016/j.jiph.2020.12.017
Horby, Mafham, Linsell, Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-center, randomized, controlled trial
Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.10.069
Kaur, Charan, Dutta, Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database, Infect Drug Resist, doi:10.2147/IDR.S287934
Kumagai, Murakawa, Hasunuma, Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults, Int J Clin Pharmacol Ther, doi:10.5414/CP202388
Lagier, Million, Gautret, Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101791
Lu, Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet
Madelain, Nguyen, Olivo, Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials, Clin Pharmacokinet, doi:10.1007/s40262-015-0364-1
Mamary, Kondapaneni, Vance, Gaughan, Martin et al., Survival in patients receiving prolonged ventilation: factors that influence outcome, Clin Med Insights Circ Respir Pulm Med
Nasir, Perveen, Saha, Talha, Selina et al., Systematic review on repurposing use of Favipiravir against SARS-CoV-2, Mymensingh Med J
Negoescu, Thornback, Wong, Ostor, Long QT and hydroxychloroquine; A poorly recognised problem in rheumatology patients, Arthritis Rheum
Perveen, Nasir, Murshed, Nazneen, Ahmad, Remdesivir and favipiravir changes hepato-renal profile in COVID-19 patients: a cross sectional observation in Bangladesh, Int J Med Sci Clin Invent, doi:10.18535/ijmsci/v8i01.03
Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world experience with favipiravir for treatment of COVID-19 in Thailand: results from a multi-center observational study, doi:10.1101/2020.06.24.20133249v3
Thai, Son, Van, Factors associated with the duration of hospitalisation among COVID-19 patients in Vietnam: a survival analysis, Epidemiol Infect
Udwadia, Singh, Barkate, Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multi-center, Phase 3 clinical trial, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.142
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Çap, Bilge, Işık, The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019, J Electrocardiol, doi:10.1016/j.jelectrocard.2020.10.015
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit